WO2008085728A3 - Combination medication for treating the effects of stomach acid reduction medication on bone integrity - Google Patents

Combination medication for treating the effects of stomach acid reduction medication on bone integrity Download PDF

Info

Publication number
WO2008085728A3
WO2008085728A3 PCT/US2007/088824 US2007088824W WO2008085728A3 WO 2008085728 A3 WO2008085728 A3 WO 2008085728A3 US 2007088824 W US2007088824 W US 2007088824W WO 2008085728 A3 WO2008085728 A3 WO 2008085728A3
Authority
WO
WIPO (PCT)
Prior art keywords
medication
treating
proton pump
effects
stomach acid
Prior art date
Application number
PCT/US2007/088824
Other languages
French (fr)
Other versions
WO2008085728A2 (en
Inventor
Renjit Sundharadas
Original Assignee
Renjit Sundharadas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renjit Sundharadas filed Critical Renjit Sundharadas
Publication of WO2008085728A2 publication Critical patent/WO2008085728A2/en
Publication of WO2008085728A3 publication Critical patent/WO2008085728A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A composition for addressing a calcium deficiency caused by chronic administration of proton pump inhibitors and other acid lowering agents comprised of at least one proton pump inhibitor and vitamin D. The composition can further include one or more of the following: at least one buffering agent in an amount sufficient to increase gastric fluid pH to a pH that prevents acid degradation of at least a portion of the proton pump inhibitor in the gastric fluid, a therapeutically effective amount of at least one non-steroidal anti-inflammatory drug, a therapeutically effective amount of at least one bisphosphonate or selective estrogen receptor modulator, and at least one calcium supplement.
PCT/US2007/088824 2007-01-06 2007-12-26 Combination medication for treating the effects of stomach acid reduction medication on bone integrity WO2008085728A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US87918807P 2007-01-06 2007-01-06
US60/879,188 2007-01-06
US95853907P 2007-07-07 2007-07-07
US60/958,539 2007-07-07
US94872907A 2007-11-30 2007-11-30
US11/948,729 2007-11-30

Publications (2)

Publication Number Publication Date
WO2008085728A2 WO2008085728A2 (en) 2008-07-17
WO2008085728A3 true WO2008085728A3 (en) 2008-09-25

Family

ID=39609241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088824 WO2008085728A2 (en) 2007-01-06 2007-12-26 Combination medication for treating the effects of stomach acid reduction medication on bone integrity

Country Status (1)

Country Link
WO (1) WO2008085728A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104703486A (en) * 2012-09-04 2015-06-10 德克萨斯大学系统董事会 Citrate-rich calcium-magnesium supplement and uses thereof
CN106924257B (en) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 Proton pump inhibitor and the compound of anti-osteoporotic and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050249806A1 (en) * 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANIS ET AL.: "Guidelines for Diagnosis and Management of Osteoporosis", OSTEOPOROS INTERNATIONAL, vol. 7, no. 4, July 1997 (1997-07-01), pages 390 - 406 *

Also Published As

Publication number Publication date
WO2008085728A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2005076987A3 (en) Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
AU2007247480A8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
WO2008016887A3 (en) Methods and pharmaceutical compositions to treat gastric acid disorders
WO2009129149A3 (en) Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
RS54543B1 (en) Fast acting inhibitor of gastric acid secretion
WO2008049657A3 (en) Use of (meth)acrylate copolymers in slow-release pharmaceutical forms for reducing the influence of ethanol on active ingredient release
WO2008118141A3 (en) Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2009129147A3 (en) Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
WO2009134057A3 (en) Pharmaceutical formulation containing angiotensin-ii receptor blocker
UA91376C2 (en) Controlled release formulation
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
MX2008010646A (en) Remedy or preventive for digestive ulcer.
EP2478894A3 (en) Compositions for treating esophageal disorders
WO2008012666A3 (en) Treatment and prevention mucositis by anthocyanidin derivatives
WO2007112274A3 (en) Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
WO2009158625A3 (en) Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
WO2006060681A3 (en) Pharmaceutical composition containing an anti-nucleating agent
WO2009063378A3 (en) Olive oil formulation for pain relief
WO2008074824A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
WO2007111945A3 (en) Method for management of diarrhea
WO2005099749A3 (en) Methods for controlling angiogenesis and cell proliferation
WO2008085728A3 (en) Combination medication for treating the effects of stomach acid reduction medication on bone integrity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869908

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07869908

Country of ref document: EP

Kind code of ref document: A2